Molecular biology of the CRH receptors - in the mood

被引:98
作者
Dautzenberg, FM
Kilpatrick, GJ
Hauger, RL
Moreau, JL
机构
[1] F Hoffmann La Roche & Co Ltd, Div Pharma, CH-4070 Basel, Switzerland
[2] CeNeS Ltd, Cambridge CB4 9ZR, England
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Vet Adm Med Ctr, Dept Psychiat, La Jolla, CA 92093 USA
关键词
corticotropin-releasing hormone; CRH receptor; alternative splicing; CRH binding pocket; CRH receptor deficient mice;
D O I
10.1016/S0196-9781(01)00388-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysfunctioning of corticotropin-releasing hormone (CRH) and its receptors (CRH1 and CRH2) has been linked to the development of stress-related disorders. such as mood and eating disorders. The molecular characterization of CRH1 and CRH2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. While mammalian CRH1 receptors nonselectively bind CRH analogs. the ligand specificity of CRH2 is narrower. CRH1 receptors are predominantly expressed in the bt ain and pituitary, whereas CRH2 receptor expression is limited to particular brain areas and to some peripheral organs. Molecular approaches to block CRH1 receptor expression in the brain argue in favor of its involvement in the regulation of some aspects of the stress response. The CRH2 alpha receptor may be more important for motivational types of behavior essential for survival, such as feeding and defense. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:753 / 760
页数:8
相关论文
共 70 条
[11]   The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile [J].
Dautzenberg, FM ;
Kilpatrick, GJ ;
Wille, S ;
Hauger, RL .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) :821-829
[12]   Evidence for the abundant expression of arginine 185 containing human CRF2α receptors and the role of position 185 for receptor-ligand selectivity [J].
Dautzenberg, FM ;
Huber, G ;
Higelin, J ;
Py-Lang, G ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 2000, 39 (08) :1368-1376
[13]   The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress [J].
Deak, T ;
Nguyen, KT ;
Ehrlich, AL ;
Watkins, LR ;
Spencer, RL ;
Maier, SF ;
Licinio, J ;
Wong, ML ;
Chrousos, GP ;
Webster, E ;
Gold, PW .
ENDOCRINOLOGY, 1999, 140 (01) :79-86
[14]   Cloning and characterization of human urocortin [J].
Donaldson, CJ ;
Sutton, SW ;
Perrin, MH ;
Corrigan, AZ ;
Lewis, KA ;
Rivier, JE ;
Vaughan, JM ;
Vale, WW .
ENDOCRINOLOGY, 1996, 137 (05) :2167-2170
[15]   Labelling of CRF1 and CRF2 receptors using the novel radioligand, [H-3]-urocortin [J].
Gottowik, J ;
Goetschy, V ;
Henriot, S ;
Kitas, E ;
Fluhman, B ;
Clerc, RG ;
Moreau, JL ;
Monsma, FJ ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 1997, 36 (10) :1439-1446
[16]   A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes [J].
Grammatopoulos, DK ;
Dai, YL ;
Randeva, HS ;
Levine, MA ;
Karteris, E ;
Easton, AJ ;
Hillhouse, EW .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (12) :2189-2202
[17]  
Griebel G, 1998, PSYCHOPHARMACOLOGY, V138, P55
[18]  
Grigoriadis DE, 1996, MOL PHARMACOL, V50, P679
[19]   POTENT, STRUCTURALLY CONSTRAINED AGONISTS AND COMPETITIVE ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR [J].
GULYAS, J ;
RIVIER, C ;
PERRIN, M ;
KOERBER, SC ;
SUTTON, S ;
CORRIGAN, A ;
LAHRICHI, SL ;
CRAIG, AG ;
VALE, W ;
RIVIER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10575-10579
[20]  
Hauger RL, 2000, NEUROENDOCRINOLOGY IN PHYSIOLOGY AND MEDICINE, P261